ADvocate 1 Archives - Medical Conferences

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

Can lebrikizumab maintain response rates in atopic dermatitis?

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ADvocate 1 and ADvocate 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:58

IL-13 inhibition with lebrikizumab shows high maintenance rates in AD

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, ADvocate

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:05

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, ADvocate 1; ADvocate 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:18